CSF/serum IL-1β levels have been reported as a prognostic factor for epilepsy development after traumatic brain injury [21], and the brain-specific adhesion molecule ICAM5 can be used to discriminate between drug-responsive and drug-resistant epilepsy [22]. This evidence concerns the gene IL1B and epilepsy.